ArticleMedical oncology (Northwood, London, England)2013
Detection of perioperative cancer antigen 72-4 in gastric juice pre- and post-distal gastrectomy and its significances.
Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The prognostic and clinicopathologic characteristics of CD147 and esophagus cancer: A meta-analysis.PloS one · 2017Pooled it
- Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives.Molecular medicine (Cambridge, Mass.) · 2025Review
- A prognostic model based on the COL1A1-network in gastric cancer.American journal of translational research · 2023Article
- Brain metastasis from gastric adenocarcinoma: A large comprehensive population-based cohort study on risk factors and prognosis.Frontiers in oncology · 2022Article
- Effect of miR‑145 on gastric cancer cells.Molecular medicine reports · 2019Article
- Role of Helicobacter pylori infection in cancer-associated fibroblast-induced epithelial-mesenchymal transition in vitro.Helicobacter · 2018Article
- Inhibitory effects of isocryptotanshinone on gastric cancer.Scientific reports · 2018Article
- LDH-Apromotes epithelial-mesenchymal transition by upregulating ZEB2 in intestinal-type gastric cancer.OncoTargets and therapy · 2018Article
- Expression and clinical significance of CD147 in renal cell carcinoma: a meta-analysis.Oncotarget · 2017Article
- Detection of digestive malignancies and post-gastrectomy complications via gastrointestinal fluid examination.Frontiers of medicine · 2017Review
- CD147 and MMP-9 expressions in type II/III adenocarcinoma of esophagogastric junction and their clinicopathological significances.International journal of clinical and experimental pathology · 2015Article
- Epithelial-mesenchymal transition in gastric cancer.American journal of translational research · 2015Review
- Perspectives on new biomarkers in gastric cancer: diagnostic and prognostic applications.World journal of gastroenterology · 2014Review
- Adenocarcinoma of esophagogastric junction: controversial classification, surgical management, and clinicopathology.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2014Article
- Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Significance of peripheral neutrophil-lymphocyte ratio among gastric cancer patients and construction of a treatment-predictive model: a study based on 1131 cases.American journal of cancer research · 2014Article
- Up-regulation of SUMO1 pseudogene 3 (SUMO1P3) in gastric cancer and its clinical association.Medical oncology (Northwood, London, England) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric carcinoma is one of the most common malignancies nowadays, and caner antigen 72-4 (CA 72-4) in gastric juice has been rarely studied. To compare CA 72-4 in gastric juice pre- and post-distal gastrectomy (DG) and analyze its possible significances, we selected 64 patients diagnosed with gastric carcinoma who underwent DG and collected their perioperative gastric juice samples whose contents of CA 72-4 were detected. We found that CA 72-4 in gastric juice pre-gastrectomy is significantly higher among patients in advanced stages and correlated with tumor TNM classification (P < 0.01), within which tumor size, levels of gastric wall invaded, and number of metastatic lymph nodes are significant influencing factors (P < 0.05); CA 72-4 in gastric juice post-gastrectomy is significantly higher than that pre-surgery (P < 0.01), and it is significantly correlated with tumor TNM classification and radical degree (P < 0.01), and regards the sum of distances from tumor to two cutting edges and the classification of cutting edge as significant impact factors (P < 0.05); nine patients whose CA 72-4 in gastric juice rose post-DG show features indicating poor prognosis; the difference of CA 72-4 in gastric juice between pre- and post-gastrectomy is significantly correlated with tumor TNM classification and radical degree (P < 0.05), and regards tumor size, levels of gastric walls invaded, the sum of distances from tumor to two cutting edges and the classification of cutting edge as significant influential factors (P < 0.05). We conclude that CA 72-4 in gastric juice pre- and post-gastrectomy can provide us with much information about tumor and radical gastrectomy and that CA 72-4 in gastric juice post-gastrectomy and the difference of CA 72-4 in gastric juice between pre- and post-gastrectomy may indicate prognosis.
Indexed as
Identifiers
23820956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.